Literature DB >> 16924018

CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease.

P Sanchez-Juan1, A Green, A Ladogana, N Cuadrado-Corrales, R Sáanchez-Valle, E Mitrováa, K Stoeck, T Sklaviadis, J Kulczycki, K Hess, M Bodemer, D Slivarichová, A Saiz, M Calero, L Ingrosso, R Knight, A C J W Janssens, C M van Duijn, I Zerr.   

Abstract

OBJECTIVES: To analyze the diagnostic sensitivity and specificity of various brain-derived proteins (14-3-3, Tau, neuron specific enolase [NSE], and S100b) in the CSF of patients with Creutzfeldt-Jakob disease (CJD) and to analyze biologic factors that modify these parameters.
METHODS: CSF was tested for 14-3-3, Tau, NSE, and S100b in 1,859 patients with sporadic, genetic, iatrogenic, and variant CJD, and in 1,117 controls.
RESULTS: The highest sensitivity was achieved for 14-3-3 and Tau in sporadic CJD (85% and 86%), and a combined determination of 14-3-3 and Tau, S100b, or NSE increased the sensitivity to over 93%. A multivariate analysis showed that the sensitivity of all tests was highest in patients with the shortest disease duration, age at onset >40 years, and homozygosity at codon 129 of the prion protein gene. In a group of patients with repeated lumbar punctures, a second test also increased the diagnostic sensitivity.
CONCLUSIONS: The detection of elevated levels of brain-derived proteins in the CSF in patients with suspected Creutzfeldt-Jakob disease is a valuable diagnostic test. A second lumbar puncture may be of value in patients with atypical clinical course in whom the first test was negative.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924018     DOI: 10.1212/01.wnl.0000230159.67128.00

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  86 in total

1.  Subacute progressive aphasia: a rare presentation of Creutzfeldt-Jakob disease.

Authors:  Javier Riancho; Manuel Delgado-Alvarado; José Luis Fernández-Torre; Pascual Sánchez-Juan; Jose Miguel Polo
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

2.  Infectious disease - developments in the field of Creutzfeldt-Jakob disease.

Authors:  J David Beckham; Kenneth L Tyler
Journal:  Rev Neurol Dis       Date:  2007

3.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

4.  PrP mRNA and protein expression in brain and PrP(c) in CSF in Creutzfeldt-Jakob disease MM1 and VV2.

Authors:  Franc Llorens; Belén Ansoleaga; Paula Garcia-Esparcia; Saima Zafar; Oriol Grau-Rivera; Irene López-González; Rosi Blanco; Margarita Carmona; Jordi Yagüe; Carlos Nos; José Antonio Del Río; Ellen Gelpí; Inga Zerr; Isidre Ferrer
Journal:  Prion       Date:  2013-09-18       Impact factor: 3.931

5.  Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.

Authors:  Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova
Journal:  Mol Neurobiol       Date:  2016-09-24       Impact factor: 5.590

Review 6.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

7.  Voltage-gated potassium channel autoimmunity mimicking creutzfeldt-jakob disease.

Authors:  Michael D Geschwind; K Meng Tan; Vanda A Lennon; Ramon F Barajas; Aissa Haman; Christopher J Klein; S Andrew Josephson; Sean J Pittock
Journal:  Arch Neurol       Date:  2008-10

8.  Rapidly progressive neurodegenerative dementias.

Authors:  Keith A Josephs; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Brian A Crum; Caterina Giannini; Ronald C Petersen
Journal:  Arch Neurol       Date:  2009-02

9.  Matrix metalloproteinases-2 and -3 are reduced in cerebrospinal fluid with low beta-amyloid1-42 levels.

Authors:  Reinhilde Mlekusch; Christian Humpel
Journal:  Neurosci Lett       Date:  2009-09-26       Impact factor: 3.046

10.  Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis.

Authors:  Pascual Sanchez-Juan; Raquel Sánchez-Valle; Alison Green; Anna Ladogana; Natividad Cuadrado-Corrales; Eva Mitrová; Kathrina Stoeck; Theodoros Sklaviadis; Jerzy Kulczycki; Klaus Hess; Anna Krasnianski; Michele Equestre; Danka Slivarichová; Albert Saiz; Miguel Calero; Maurizio Pocchiari; Richard Knight; Cornelia M van Duijn; Inga Zerr
Journal:  J Neurol       Date:  2007-03-25       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.